- Home
- OTLK vs IMMX Comparison
OTLK vs IMMX Comparison
Compare OTLK & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- IMMX
- Stock Information
- Founded
- OTLK 2010
- IMMX 2014
- Country
- OTLK United States
- IMMX United States
- Employees
- OTLK N/A
- IMMX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- OTLK Health Care
- IMMX Health Care
- Exchange
- OTLK Nasdaq
- IMMX Nasdaq
- Market Cap
- OTLK 48.3M
- IMMX 50.1M
- IPO Year
- OTLK 2016
- IMMX 2021
- Fundamental
- Price
- OTLK $1.53
- IMMX $2.09
- Analyst Decision
- OTLK Strong Buy
- IMMX Strong Buy
- Analyst Count
- OTLK 5
- IMMX 1
- Target Price
- OTLK $10.20
- IMMX $7.00
- AVG Volume (30 Days)
- OTLK 274.9K
- IMMX 59.2K
- Earning Date
- OTLK 05-19-2025
- IMMX 05-20-2025
- Dividend Yield
- OTLK N/A
- IMMX N/A
- EPS Growth
- OTLK N/A
- IMMX N/A
- EPS
- OTLK N/A
- IMMX N/A
- Revenue
- OTLK N/A
- IMMX N/A
- Revenue This Year
- OTLK N/A
- IMMX N/A
- Revenue Next Year
- OTLK $288.46
- IMMX N/A
- P/E Ratio
- OTLK N/A
- IMMX N/A
- Revenue Growth
- OTLK N/A
- IMMX N/A
- 52 Week Low
- OTLK $0.87
- IMMX $1.26
- 52 Week High
- OTLK $9.25
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- OTLK 55.94
- IMMX 61.41
- Support Level
- OTLK $1.35
- IMMX $1.92
- Resistance Level
- OTLK $1.62
- IMMX $2.25
- Average True Range (ATR)
- OTLK 0.10
- IMMX 0.17
- MACD
- OTLK -0.00
- IMMX 0.03
- Stochastic Oscillator
- OTLK 54.55
- IMMX 67.61
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.